FDMT 4D Molecular Therapeutics Inc
Price (delayed)
$3.28
Market cap
$151.87M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.98
Enterprise value
$27.14M
4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector
Highlights
FDMT's revenue has surged by 118% since the previous quarter but it has dropped by 100% year-on-year
The gross profit has surged by 118% since the previous quarter but it has dropped by 100% year-on-year
The company's debt has surged by 68% YoY
The company's net income has shrunk by 60% YoY and by 12% QoQ
Key stats
What are the main financial stats of FDMT
Market
Valuations
Earnings
Shares outstanding
46.3M
Market cap
$151.87M
Enterprise value
$27.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.3
Price to sales (P/S)
4,782.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
733.56
Revenue
$37,000
Gross profit
$37,000
Operating income
-$187.84M
Net income
-$160.87M
EBIT
-$160.87M
EBITDA
-$154.16M
Free cash flow
-$138.37M
Per share
Balance sheet
Liquidity
EPS
-$2.98
EPS diluted
-$2.98
Free cash flow per share
-$2.57
Book value per share
$11.05
Revenue per share
$0
TBVPS
$10.39
Total assets
$560.38M
Total liabilities
$49.78M
Debt
$24.61M
Equity
$510.61M
Working capital
$405.78M
Debt to equity
0.05
Current ratio
14.92
Quick ratio
14.58
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-416,656.8%
Gross margin
100%
Net margin
-434,778.4%
Operating margin
-507,678.4%
Return on assets
-26.7%
Return on equity
-28.6%
Return on invested capital
-40.3%
Return on capital employed
-30.3%
Return on sales
-434,778.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FDMT stock price
How has the 4D Molecular Therapeutics stock price performed over time
Intraday
9.7%
1 week
-9.14%
1 month
-27.59%
1 year
-88.28%
YTD
-41.11%
QTD
1.55%
Financial performance
How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$37,000
Gross profit
$37,000
Operating income
-$187.84M
Net income
-$160.87M
Gross margin
100%
Net margin
-434,778.4%
FDMT's revenue has surged by 118% since the previous quarter but it has dropped by 100% year-on-year
The gross profit has surged by 118% since the previous quarter but it has dropped by 100% year-on-year
The operating income has shrunk by 66% YoY and by 12% QoQ
The company's net income has shrunk by 60% YoY and by 12% QoQ
Growth
What is 4D Molecular Therapeutics's growth rate over time
Valuation
What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
0.3
P/S
4,782.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
733.56
4D Molecular Therapeutics's EPS has decreased by 16% YoY and by 4.6% from the previous quarter
The stock's P/B is 88% below its 5-year quarterly average of 2.3 and 82% below its last 4 quarters average of 1.5
The company's equity has surged by 66% YoY but it fell by 8% QoQ
FDMT's revenue has surged by 118% since the previous quarter but it has dropped by 100% year-on-year
The P/S is 65% higher than the 5-year quarterly average of 2640.7 but 60% lower than the last 4 quarters average of 10895.2
Efficiency
How efficient is 4D Molecular Therapeutics business performance
The return on invested capital has surged by 54% year-on-year and by 10% since the previous quarter
4D Molecular Therapeutics's ROS has increased by 48% from the previous quarter
The return on equity is up by 16% year-on-year but it has declined by 2.1% since the previous quarter
The ROA has grown by 14% YoY
Dividends
What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FDMT.
Financial health
How did 4D Molecular Therapeutics financials performed over time
4D Molecular Therapeutics's total assets has soared by 65% YoY but it has decreased by 7% from the previous quarter
The total liabilities has soared by 55% YoY but it has contracted by 2.5% from the previous quarter
The company's debt is 95% lower than its equity
The company's debt has surged by 68% YoY
The company's equity has surged by 66% YoY but it fell by 8% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.